Evidence reviews – June 2021
The following documents contain the evidence that was used to develop the 2021 recommendations:
- Information and support
- Skin care advice for people with acne vulgaris
- Dietary interventions for the treatment of acne vulgaris
- Referral to specialist care
- Management options for mild to moderate acne – network meta-analyses
- Management options for mild to moderate acne – pairwise comparisons
- Management options for moderate to severe acne – network meta-analyses
- Management options for moderate to severe acne – pairwise comparisons
- Management options for people with acne vulgaris and polycystic ovary syndrome
- Management options for refractory acne
- Maintenance treatment for acne vulgaris
- Addition of oral corticosteroids to oral isotretinoin for the treatment of severe inflammatory acne vulgaris
- Intralesional corticosteroids for the treatment of individual acne vulgaris lesions
- Risk factors for scarring due to acne vulgaris
- Management of acne vulgaris-associated scarring
Supplements
Mild to moderate acne:
- Technical Support Unit (TSU) network meta-analysis (NMA) software code
- NMA data
- NMA of efficacy – included and excluded studies
- NMA, direct and indirect estimates
Moderate to severe acne:
This page was last updated: